カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のライビズマブ・バイオシミラー市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Raibizumab Biosimilars Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22MY8951）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22MY8951
■ 発行日：2022年5月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：127
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のライビズマブ・バイオシミラー市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ライビズマブ・バイオシミラー市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のライビズマブ・バイオシミラーの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ライビズマブ・バイオシミラー市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・AMD、CNV、DME

用途別セグメントは次のように区分されます。
・ARMD、糖尿病性網膜症、黄斑浮腫

世界のライビズマブ・バイオシミラー市場の主要な市場プレーヤーは以下のとおりです。
・Roche、Novartis、Genentech、Pfizer、Sartorius、Eli Lilly、Bayer、Amgen、PlantForm、PharmaPraxis、Samsung Bioepis、Centus、Cadila Pharmaceuticals、Dr Reddy's、Aurobindo Pharma、Biocad、MAbxience、Hetero、Biocon、Kirin Biologics、Mylan、BeiGene、Innovent、Qilu Pharmaceutical、Hengrui Pharmaceuticals、Hisun Pharmaceutical、TOT BIOPHARM、Luye Pharmaceutical、Henlius

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ライビズマブ・バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なライビズマブ・バイオシミラーメーカーの企業概要、2019年～2022年までのライビズマブ・バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なライビズマブ・バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ライビズマブ・バイオシミラーの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのライビズマブ・バイオシミラーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのライビズマブ・バイオシミラー市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびライビズマブ・バイオシミラーの産業チェーンを掲載しています。
・第13、14、15章では、ライビズマブ・バイオシミラーの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Roche、Novartis、Genentech、Pfizer、Sartorius、Eli Lilly、Bayer、Amgen、PlantForm、PharmaPraxis、Samsung Bioepis、Centus、Cadila Pharmaceuticals、Dr Reddy's、Aurobindo Pharma、Biocad、MAbxience、Hetero、Biocon、Kirin Biologics、Mylan、BeiGene、Innovent、Qilu Pharmaceutical、Hengrui Pharmaceuticals、Hisun Pharmaceutical、TOT BIOPHARM、Luye Pharmaceutical、Henlius
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：AMD、CNV、DME
・用途別分析2017年-2028年：ARMD、糖尿病性網膜症、黄斑浮腫
・ライビズマブ・バイオシミラーの北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・ライビズマブ・バイオシミラーのヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・ライビズマブ・バイオシミラーのアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・ライビズマブ・バイオシミラーの南米市場規模2017年-2028年：ブラジル、アルゼンチン
・ライビズマブ・バイオシミラーの中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Raibizumab Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Raibizumab Biosimilars market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. ARMD accounting for % of the Raibizumab Biosimilars global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While AMD segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Raibizumab Biosimilars include Roche, Novartis, Genentech, Pfizer, and Sartorius, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Raibizumab Biosimilars market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
AMD
CNV
DME
Market segment by Application can be divided into
ARMD
Diabetic Retinopathy
Macular Edema
The key market players for global Raibizumab Biosimilars market are listed below:
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy’s
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Raibizumab Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Raibizumab Biosimilars, with price, sales, revenue and global market share of Raibizumab Biosimilars from 2019 to 2022.
Chapter 3, the Raibizumab Biosimilars competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Raibizumab Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Raibizumab Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Raibizumab Biosimilars.
Chapter 13, 14, and 15, to describe Raibizumab Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Raibizumab Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Raibizumab Biosimilars Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 AMD
1.2.3 CNV
1.2.4 DME
1.3 Market Analysis by Application
1.3.1 Overview: Global Raibizumab Biosimilars Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 ARMD
1.3.3 Diabetic Retinopathy
1.3.4 Macular Edema
1.4 Global Raibizumab Biosimilars Market Size & Forecast
1.4.1 Global Raibizumab Biosimilars Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Raibizumab Biosimilars Sales in Volume (2017-2028)
1.4.3 Global Raibizumab Biosimilars Price (2017-2028)
1.5 Global Raibizumab Biosimilars Production Capacity Analysis
1.5.1 Global Raibizumab Biosimilars Total Production Capacity (2017-2028)
1.5.2 Global Raibizumab Biosimilars Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Raibizumab Biosimilars Market Drivers
1.6.2 Raibizumab Biosimilars Market Restraints
1.6.3 Raibizumab Biosimilars Trends Analysis
2 Manufacturers Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Raibizumab Biosimilars Product and Services
2.1.4 Roche Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Raibizumab Biosimilars Product and Services
2.2.4 Novartis Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Genentech
2.3.1 Genentech Details
2.3.2 Genentech Major Business
2.3.3 Genentech Raibizumab Biosimilars Product and Services
2.3.4 Genentech Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Raibizumab Biosimilars Product and Services
2.4.4 Pfizer Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Sartorius
2.5.1 Sartorius Details
2.5.2 Sartorius Major Business
2.5.3 Sartorius Raibizumab Biosimilars Product and Services
2.5.4 Sartorius Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Raibizumab Biosimilars Product and Services
2.6.4 Eli Lilly Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Bayer
2.7.1 Bayer Details
2.7.2 Bayer Major Business
2.7.3 Bayer Raibizumab Biosimilars Product and Services
2.7.4 Bayer Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Raibizumab Biosimilars Product and Services
2.8.4 Amgen Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 PlantForm
2.9.1 PlantForm Details
2.9.2 PlantForm Major Business
2.9.3 PlantForm Raibizumab Biosimilars Product and Services
2.9.4 PlantForm Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 PharmaPraxis
2.10.1 PharmaPraxis Details
2.10.2 PharmaPraxis Major Business
2.10.3 PharmaPraxis Raibizumab Biosimilars Product and Services
2.10.4 PharmaPraxis Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Samsung Bioepis
2.11.1 Samsung Bioepis Details
2.11.2 Samsung Bioepis Major Business
2.11.3 Samsung Bioepis Raibizumab Biosimilars Product and Services
2.11.4 Samsung Bioepis Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Centus
2.12.1 Centus Details
2.12.2 Centus Major Business
2.12.3 Centus Raibizumab Biosimilars Product and Services
2.12.4 Centus Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Cadila Pharmaceuticals
2.13.1 Cadila Pharmaceuticals Details
2.13.2 Cadila Pharmaceuticals Major Business
2.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Product and Services
2.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Dr Reddy’s
2.14.1 Dr Reddy’s Details
2.14.2 Dr Reddy’s Major Business
2.14.3 Dr Reddy’s Raibizumab Biosimilars Product and Services
2.14.4 Dr Reddy’s Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Aurobindo Pharma
2.15.1 Aurobindo Pharma Details
2.15.2 Aurobindo Pharma Major Business
2.15.3 Aurobindo Pharma Raibizumab Biosimilars Product and Services
2.15.4 Aurobindo Pharma Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Biocad
2.16.1 Biocad Details
2.16.2 Biocad Major Business
2.16.3 Biocad Raibizumab Biosimilars Product and Services
2.16.4 Biocad Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 MAbxience
2.17.1 MAbxience Details
2.17.2 MAbxience Major Business
2.17.3 MAbxience Raibizumab Biosimilars Product and Services
2.17.4 MAbxience Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Hetero
2.18.1 Hetero Details
2.18.2 Hetero Major Business
2.18.3 Hetero Raibizumab Biosimilars Product and Services
2.18.4 Hetero Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Biocon
2.19.1 Biocon Details
2.19.2 Biocon Major Business
2.19.3 Biocon Raibizumab Biosimilars Product and Services
2.19.4 Biocon Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20 Kirin Biologics
2.20.1 Kirin Biologics Details
2.20.2 Kirin Biologics Major Business
2.20.3 Kirin Biologics Raibizumab Biosimilars Product and Services
2.20.4 Kirin Biologics Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21 Mylan
2.21.1 Mylan Details
2.21.2 Mylan Major Business
2.21.3 Mylan Raibizumab Biosimilars Product and Services
2.21.4 Mylan Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22 BeiGene
2.22.1 BeiGene Details
2.22.2 BeiGene Major Business
2.22.3 BeiGene Raibizumab Biosimilars Product and Services
2.22.4 BeiGene Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23 Innovent
2.23.1 Innovent Details
2.23.2 Innovent Major Business
2.23.3 Innovent Raibizumab Biosimilars Product and Services
2.23.4 Innovent Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24 Qilu Pharmaceutical
2.24.1 Qilu Pharmaceutical Details
2.24.2 Qilu Pharmaceutical Major Business
2.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Product and Services
2.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25 Hengrui Pharmaceuticals
2.25.1 Hengrui Pharmaceuticals Details
2.25.2 Hengrui Pharmaceuticals Major Business
2.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Product and Services
2.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.26 Hisun Pharmaceutical
2.26.1 Hisun Pharmaceutical Details
2.26.2 Hisun Pharmaceutical Major Business
2.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Product and Services
2.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.27 TOT BIOPHARM
2.27.1 TOT BIOPHARM Details
2.27.2 TOT BIOPHARM Major Business
2.27.3 TOT BIOPHARM Raibizumab Biosimilars Product and Services
2.27.4 TOT BIOPHARM Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.28 Luye Pharmaceutical
2.28.1 Luye Pharmaceutical Details
2.28.2 Luye Pharmaceutical Major Business
2.28.3 Luye Pharmaceutical Raibizumab Biosimilars Product and Services
2.28.4 Luye Pharmaceutical Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.29 Henlius
2.29.1 Henlius Details
2.29.2 Henlius Major Business
2.29.3 Henlius Raibizumab Biosimilars Product and Services
2.29.4 Henlius Raibizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Raibizumab Biosimilars Breakdown Data by Manufacturer
3.1 Global Raibizumab Biosimilars Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Raibizumab Biosimilars Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Raibizumab Biosimilars
3.4 Market Concentration Rate
3.4.1 Top 3 Raibizumab Biosimilars Manufacturer Market Share in 2021
3.4.2 Top 6 Raibizumab Biosimilars Manufacturer Market Share in 2021
3.5 Global Raibizumab Biosimilars Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Raibizumab Biosimilars Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Raibizumab Biosimilars Market Size by Region
4.1.1 Global Raibizumab Biosimilars Sales in Volume by Region (2017-2028)
4.1.2 Global Raibizumab Biosimilars Revenue by Region (2017-2028)
4.2 North America Raibizumab Biosimilars Revenue (2017-2028)
4.3 Europe Raibizumab Biosimilars Revenue (2017-2028)
4.4 Asia-Pacific Raibizumab Biosimilars Revenue (2017-2028)
4.5 South America Raibizumab Biosimilars Revenue (2017-2028)
4.6 Middle East and Africa Raibizumab Biosimilars Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Raibizumab Biosimilars Sales in Volume by Type (2017-2028)
5.2 Global Raibizumab Biosimilars Revenue by Type (2017-2028)
5.3 Global Raibizumab Biosimilars Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Raibizumab Biosimilars Sales in Volume by Application (2017-2028)
6.2 Global Raibizumab Biosimilars Revenue by Application (2017-2028)
6.3 Global Raibizumab Biosimilars Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Raibizumab Biosimilars Sales by Type (2017-2028)
7.2 North America Raibizumab Biosimilars Sales by Application (2017-2028)
7.3 North America Raibizumab Biosimilars Market Size by Country
7.3.1 North America Raibizumab Biosimilars Sales in Volume by Country (2017-2028)
7.3.2 North America Raibizumab Biosimilars Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Raibizumab Biosimilars Sales by Type (2017-2028)
8.2 Europe Raibizumab Biosimilars Sales by Application (2017-2028)
8.3 Europe Raibizumab Biosimilars Market Size by Country
8.3.1 Europe Raibizumab Biosimilars Sales in Volume by Country (2017-2028)
8.3.2 Europe Raibizumab Biosimilars Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Raibizumab Biosimilars Sales by Type (2017-2028)
9.2 Asia-Pacific Raibizumab Biosimilars Sales by Application (2017-2028)
9.3 Asia-Pacific Raibizumab Biosimilars Market Size by Region
9.3.1 Asia-Pacific Raibizumab Biosimilars Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Raibizumab Biosimilars Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Raibizumab Biosimilars Sales by Type (2017-2028)
10.2 South America Raibizumab Biosimilars Sales by Application (2017-2028)
10.3 South America Raibizumab Biosimilars Market Size by Country
10.3.1 South America Raibizumab Biosimilars Sales in Volume by Country (2017-2028)
10.3.2 South America Raibizumab Biosimilars Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Raibizumab Biosimilars Sales by Type (2017-2028)
11.2 Middle East & Africa Raibizumab Biosimilars Sales by Application (2017-2028)
11.3 Middle East & Africa Raibizumab Biosimilars Market Size by Country
11.3.1 Middle East & Africa Raibizumab Biosimilars Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Raibizumab Biosimilars Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Raibizumab Biosimilars and Key Manufacturers
12.2 Manufacturing Costs Percentage of Raibizumab Biosimilars
12.3 Raibizumab Biosimilars Production Process
12.4 Raibizumab Biosimilars Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Raibizumab Biosimilars Typical Distributors
13.3 Raibizumab Biosimilars Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のオマリズマブ・バイオシミラー市場2022年：市場規模予測（～2028年）
  • 世界のアフリベルセプトバイオシミラー市場2022年：市場規模予測（～2028年）
  • 世界の携帯型レスピレーター市場2022年：市場規模予測（～2028年）
  • 世界のN95マスク市場2022年：市場規模予測（～2028年）
  • 世界の移動式DR市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22MY8951 )"世界のライビズマブ・バイオシミラー市場2022年：市場規模予測（～2028年）" (英文：Global Raibizumab Biosimilars Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。